Translational Development Acquisition Corp.
TDAC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | -14.3% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | 15.1% | 27.4% | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -115.3% | -155.2% | – |
| Other Income/Exp. Net | $2 | $2 | $2 | $0 |
| Pre-Tax Income | $2 | $2 | $1 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $2 | $2 | $1 | -$0 |
| % Margin | – | 846.5% | 662.5% | – |
| EPS | 0.08 | 0.074 | 0.37 | -0.002 |
| % Growth | 8% | -80% | 24,766.7% | – |
| EPS Diluted | 0.08 | 0.074 | 0.37 | -0.002 |
| Weighted Avg Shares Out | 17 | 17 | 4 | 4 |
| Weighted Avg Shares Out Dil | 17 | 17 | 4 | 4 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | -$0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | -$0 |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | – | -115.3% | -155.2% | – |